Pulmicort contains a powerful non-halogenated corticosteroid-budesonide, intended for the treatment of bronchial asthma in patients for whom the use of inhalers with the spray of medicinal substances with compressed air or in the form of a medicinal form of dry powder is ineffective or impractical. Pulmicort is also recommended for use in infants and children with croup (a complication of acute upper respiratory viral infection, also known as laryngotracheobronchitis or sublingular laryngitis), which is an indication for hospitalization.
Pulmicort Composition and form of release
It is made in the form of a metered suspension or powder for inhalation. The main active ingredient of the drug is budesonide.
Pulmicort is used in the treatment of chronic obstructive pulmonary disease and bronchial asthma, which requires maintenance therapy with glucocorticosteroid drugs.
Pulmicort is not used for hypersensitivity to budesonide and in the treatment of children under 6 months of age.
Care should be taken when prescribing Pulmicort for patients who have been diagnosed with an active or inactive form of pulmonary tuberculosis, cirrhosis of the liver, viral, bacterial or fungal infections of the respiratory system.
Applies to children from 6 months.
Application during pregnancy and lactation
The use of Pulmicort in the treatment of pregnant women is possible for strict medical reasons and only if the potential benefits of its use significantly outweigh the risk to the fetus. In connection with the fact that in some patients pregnancy causes a worsening of the course of bronchial asthma, one should be especially responsible for the selection of the minimum effective dose of the drug. During the studies, Pulmicort did not reveal a teratogenic or mutagenic effect, which allows the drug to be used to treat this category of patients. If during pregnancy a woman received treatment with Pulmicort, then the newborn must constantly monitor the correctness of the adrenal glands.
Pulmicort is able to penetrate into breast milk, but when the drug is used in therapeutic doses, it does not have a negative effect on the health of the child.
Method of administration and dosage
Pulmicort is used to prevent the development of exacerbations of bronchial asthma. The use of the drug during an acute attack of bronchial asthma is not effective. When using Pulmicort, the likelihood of systemic effects is very low, which allows, if necessary, to increase the dosage of the drug to 1000 mcg, which makes it an excellent alternative to the combination of the drug with oral forms of glucocorticosteroids. When switching from treatment with oral glucocorticosteroid drugs to Pulmicort therapy, you should take glucocorticosteroid drugs in the prescribed dosage for another 10 days, combining their use with the new drug. Ten days later, they begin to gradually reduce the dose of glucocorticosteroid drugs to the minimum effective dose, which allows in some cases to completely abandon the intake of these drugs.
When used to obtain the drug Nibulizer, the dose of Pulmicort is selected by the doctor individually. If the dose of the drug does not exceed 1000 mcg, then it can be taken in one dose.
The starting dose of the drug for the treatment of children older than 6 months varies from 250 to 500 mcg per day, for an adult – from 1000 to 2000 mcg per day.
In acute overdose with Pulmicort, the development of any clinically significant symptoms is not observed.
In chronic overdose, patients may experience the effects of hypercortisolism, characterized by arterial hypertension, muscle weakness, amenorrhea, weight gain and hyperpigmentation. To stabilize the patient’s condition, gradual withdrawal of the drug is recommended.
In most cases, treatment with Pulmicort is well tolerated by patients, however, in some cases, patients develop cough, candidal lesions of the oropharynx, irritation of the oral mucosa, increased nervous excitability, depression and various allergic reactions.
Storage conditions and periods
It is recommended to store Pulmicort in a cool place out of the reach of children and protected from light.
The term of storage of the drug is 2 years, after opening the envelope 3 months and 12 hours after opening the container.